Hamid Amini | Oncology Management | Editorial Board Member

Published on by Oncology

Dr. Hamid Amini | Oncology Management | Editorial Board Member 

Tolou-e- Mehr Non-profit Institute of Higher Education | Iran

Hamid Amini is an Iranian researcher and academic affiliated with the Department of Physical Education and Sport Sciences at Tolou-e-Mehr Non-profit Institute of Higher Education in Qom, whose scholarly work centers on exercise physiology, physical activity, and the interaction between physical training, health, and disease prevention. His research portfolio reflects a strong interdisciplinary approach that integrates sports science with public health, immunology, neurodegeneration, and molecular biology. Amini has contributed significantly to understanding how different forms of physical activity influence inflammatory markers, oxidative stress, immune responses, and functional capacity across diverse populations, including women with multiple sclerosis, elderly women, COVID-19 patients, and animal models of Alzheimer’s disease. During the COVID-19 pandemic, his work gained particular relevance through studies examining physical inactivity trends, the relationship between pre-disease activity levels and disease severity, and the need to update global physical activity policies, highlighting his engagement with population-level health challenges. He has also explored exercise-induced muscle damage and recovery, investigating interventions such as herbal supplements, vibration therapy, vitamin D, and combined pharmacological and natural treatments to mitigate delayed-onset muscle soreness and related biochemical changes. Beyond applied human studies, his publications include experimental research on molecular pathways, cytokine expression, heat shock proteins, and growth factors influenced by aerobic and resistance training, demonstrating methodological breadth from clinical to laboratory-based research. In addition, Amini has examined organizational and educational dimensions of physical education, including empowerment, organizational learning, and tacit knowledge transfer among educators, reflecting an interest in both human performance and institutional effectiveness. His work has appeared in a range of international journals and book chapters, and he actively contributes to the scientific community through peer review for multidisciplinary journals. Overall, Hamid Amini’s research profile illustrates a sustained commitment to advancing evidence-based exercise science with clear implications for health promotion, disease management, and public policy.

Profile: ORCID

Featured Publications

Amini, H., Habibi, S., Islamoglu, A. H., Isanejad, E., Uz, C., & Daniyari, H. (2021). COVID-19 pandemic-induced physical inactivity: The necessity of updating the Global Action Plan on Physical Activity 2018–2030. Environmental Health and Preventive Medicine, 26, Article 1.

Amini, H., Isanejad, A., Chamani, N., Movahedi-Fard, F., Salimi, F., Moezi, M., & Habibi, S. (2020). Physical activity during COVID-19 pandemic in the Iranian population: A brief report. Heliyon, 6(11), e05411.

Amini, H., Tadayon Zadeh, F., Habibi, S., Shahedi, V., Isanejad, A., & Akbarpour, M. (2020). The effects of 8-week combined exercise training on inflammatory markers in women with multiple sclerosis. Neurodegenerative Diseases, 20, 1–8.

Naghavi-Azad, E., Rahmati-Ahmadabad, S., Amini, H., Azizbeigi, K., Helalizadeh, M., Iraji, R., Cornish, S. M., Khojasteh, Z., & Azarbayjani, M. A. (2020). Effects of simultaneous intake of chamomile and ibuprofen on delayed-onset muscle soreness markers and some liver enzymes following eccentric exercise. German Journal of Exercise and Sport Research, 50, 468–477.

Liu, W., Akbarpour-Beni, M., Movahed, S., Gorzi, A., Cheraghi, E., & Amini, H. (2023). Neutralising the testosterone enanthate-induced oxidative stress in rats’ uterine tissue by propolis and chicory as natural antioxidants. Comparative Exercise Physiology, 19, 1–9.

The nominee’s research advances exercise physiology and public health by generating evidence on how physical activity and targeted interventions modulate inflammation, oxidative stress, and functional capacity across clinical and population settings. His work informs disease prevention strategies, rehabilitation practices, and health policy, particularly during global challenges such as the COVID-19 pandemic. By bridging laboratory science, clinical research, and community health, his contributions support sustainable, evidence-based approaches to improving population well-being.

Prof Dr. ClausGarbe – Oncology Management and Prevention – Lifetime achievement Award

Published on by Oncology

Prof Dr. ClausGarbe - Oncology Management and Prevention - Lifetime achievement Award

University of Tuebingen - Germany

AUTHOR PROFILE

Google Scholar

Scopus

Orcid

EARLY ACADEMIC PURSUITS:

Professor Claus Garbe embarked on his academic journey by obtaining his MD from the Free University of Berlin in 1983. Following this, he pursued board certification in Dermatology and Venereology in 1987. His early academic pursuits laid the foundation for his subsequent groundbreaking work in dermatology and oncology.

PROFESSIONAL ENDEAVORS:

In 1990, Professor Garbe achieved his habilitation, akin to a PhD equivalent, with a focus on the biology of melanoma cells. This marked a significant milestone in his academic career, demonstrating his commitment to advancing the understanding of melanoma, a deadly form of skin cancer. In 1995, he transitioned to Eberhard Karls University, Tuebingen, where he assumed the role of University Professor of Dermatology and Head of the Division of Dermatooncology. This move expanded his scope of influence and provided a platform for furthering his research and clinical endeavors.

CONTRIBUTIONS AND RESEARCH FOCUS ON ONCOLOGY MANAGEMENT AND PREVENTION

Professor Garbe's contributions to the field of dermatology and oncology are extensive and profound. His principal research interests encompass the biology and genetics of melanoma and keratinocyte skin cancers, therapeutic trials in skin diseases, epidemiologic studies, and dermato-histopathology. Through his pioneering research, he has elucidated crucial mechanisms underlying skin cancer development and progression, paving the way for innovative therapeutic approaches and preventive strategies.

IMPACT AND INFLUENCE:

Professor Garbe's impact on the field of dermatologic oncology is unparalleled. His leadership roles in numerous multicenter clinical trials since 1989 have facilitated the translation of research findings into clinical practice, ultimately improving patient outcomes. Moreover, his presidency of the European Association of Dermatologic Oncology (EADO) underscores his influence on a global scale, driving collaboration and innovation in the fight against skin cancer.

ACADEMIC CITATIONS:

With over 800 articles and 17 textbooks to his name, Professor Garbe's scholarly output is prolific. His impressive H-index of 116 points reflects the significant impact of his work within the scientific community. His research findings have been cited extensively, highlighting their relevance and contribution to advancing knowledge in dermatology and oncology.

LEGACY AND FUTURE CONTRIBUTIONS:

Professor Garbe's legacy is characterized by his unwavering dedication to advancing the field of dermatologic oncology. His contributions have not only expanded our understanding of skin cancer but have also shaped clinical practice and guidelines. As he continues to spearhead research efforts and mentor the next generation of scientists and clinicians, his legacy is poised to endure, leaving an indelible mark on the field for years to come.

NOTABLE PUBLICATIONS

Sentinel lymph node biopsy is unreliable in predicting melanoma mortality for both younger and older patients. 2024 (2)

Sentinel lymph node biopsy for lentigo maligna melanoma under local anaesthesia. 2024 (3)

Epidemiology of Keratinocyte Skin Cancer with a Focus on Cutaneous Squamous Cell Carcinoma. 2024 (1)

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment–Update 2023. 2023 (6)

Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial. 2023 (2)